^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    AZD5991 (MCL1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

    Published date:
    11/06/2019
    Excerpt:
    The combination was also synergistic in leukemia cell lines lacking wild-type TP53 such as KG-1 and U937 . Importantly, the combined inhibition was more effective than each single agent in primary AML cells and stem/progenitor cells lacking wild-type TP53 due to deletion of chromosome 17 or mutations in TP53 gene.
    DOI:
    10.1182/blood-2019-124826